Drug Profile
VTX 1463
Alternative Names: VTX-1463Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Celgene Corporation
- Class Antiallergics; Small molecules
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Allergic-rhinitis in Austria (Intranasal)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Allergic-rhinitis(In volunteers) in Netherlands (Intranasal)
- 11 Jan 2021 Phase I development is ongoing for Allergic rhinitis in Australia and Netherlands (Ligand Pharmaceuticals pipeline, January 2021 )